Vaccine Therapy and Chemotherapy With or Without Tetanus Toxoid Compared With Chemotherapy Alone in Treating Patients With Metastatic Colorectal Cancer
Public ClinicalTrials.gov record NCT00027833. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Pilot Phase II Study of Safety and Immunogenicity of an ALVAC-CEA/B7.1 Vaccine Administered With Chemotherapy, Alone or in Combination With Tetanus Toxoid, as Compared to Chemotherapy Alone, in Patients With Metastatic Colorectal Adenocarcinoma
Study identification
- NCT ID
- NCT00027833
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Herbert Irving Comprehensive Cancer Center
- Other
- Enrollment
- Not listed
Conditions and interventions
Conditions
Interventions
- ALVAC-CEA-B7.1 vaccine Biological
- FOLFIRI regimen Drug
- fluorouracil Drug
- irinotecan hydrochloride Drug
- leucovorin calcium Drug
- tetanus toxoid Biological
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2001
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Jan 5, 2014
Started 2001
United States locations
- U.S. sites
- 10
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham Comprehensive Cancer Center | Birmingham | Alabama | 35243 | — |
| USC/Norris Comprehensive Cancer Center and Hospital | Los Angeles | California | 90033-0804 | — |
| Lombardi Cancer Center | Washington D.C. | District of Columbia | 20007 | — |
| H. Lee Moffitt Cancer Center and Research Institute | Tampa | Florida | 33612-9497 | — |
| Robert H. Lurie Comprehensive Cancer Center, Northwestern University | Chicago | Illinois | 60611 | — |
| University of Chicago Cancer Research Center | Chicago | Illinois | 60637-1470 | — |
| Herbert Irving Comprehensive Cancer Center | New York | New York | 10032 | — |
| Earle A. Chiles Research Institute at Providence Portland Medical Center | Portland | Oregon | 97213-2967 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| Scranton Hematology-Oncology | Scranton | Pennsylvania | 18510 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00027833, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 5, 2014 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00027833 live on ClinicalTrials.gov.